Overview

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Status:
Completed

Trial end date:
2018-07-10

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).

Phase:

Phase 3

Details

Lead Sponsor:

Cutanea Life Sciences, Inc.
Maruho Co., Ltd.

Treatments:

Furosemide